SCIENCE CHINA Materials, Volume 60, Issue 6: 504-510(2017) https://doi.org/10.1007/s40843-016-5163-4

Cell membrane-coated nanoparticles for tumor-targeted drug delivery

More info
  • ReceivedNov 27, 2016
  • AcceptedDec 20, 2016
  • PublishedJan 22, 2017


Nanoparticles can be enriched at tumor site and improve the therapeutic efficacy of many chemotherapy drugs with the well-known enhanced permeability and retention (EPR) effect. While conventional preparations of materials for nanoscale drug delivery system mainly focused on chemical synthesis, recently the combination of synthetic carrier and natural biomimetic carrier has gained more and more attention. As a new generation of biomimetic nanoparticles, cell membrane-coated nanoparticles combine the complex biological functions of natural membranes and the physicochemical properties of synthetic nanomaterials for a more effective drug delivery. Herein, we briefly review the recent advances on cell membrane-coated nanoparticles for tumor-targeted drug delivery via the prolonging systemic circulation lifetime and the active targeting effect. Since the preferential accumulation of cell membrane-coated nanoparticles in tumor site, they are able to improve the therapeutic efficacy of conventional chemotherapy drugs in antitumor treatment as well as to reduce the systemic toxicity. We also introduce a systematic targeted strategy for the promising application of this platform on brain tumors.

Funded by

National Basic Research Program of China(2013CB932500)

National Natural Science Foundation of China(81273458,81473149)


This work was supported by the National Basic Research Program of China (2013CB932500), and the National Natural Science Foundation of China (81273458 and 81473149).

Interest statement

The authors declare that they have no conflict of interest.

Contributions statement

Lu W proposed the review of tumor-targeted cell membrane-coated nanoparticles. Chai Z investigated literatures and wrote the paper. All authors contributed to the general discussion.

Author information

Zhilan Chai is a graduate student from the Department of Pharmaceutics, School of Pharmacy, Fudan University. She got her BCs degree in pharmacy from Fudan University (2011). In 2015, she joined Prof. Weiyue Lu’s group for further study. Her current research interests focus on red blood cell membrane coated-nanoparticle and its brain-targeting strategy.

Weiyue Lu is a professor at the Department of Pharmaceutics, School of Pharmacy, Fudan University, the Director of Key laboratory of Smart Drug Delivery (Fudan University), Ministry of Education, China, the Principle Investigator of National Basic Research Program (973), and the Director of the Pharmaceutics Committee and Associate Director of the Nanomedicine Committee of Chinese Pharmaceutical Association (CPA). Professor Lu’s research focuses on brain, lymphatic system and its tumor targeting strategy and drug delivery system.


[1] Wang F, Gao W, Thamphiwatana S, et al. Hydrogel retaining toxin-absorbing nanosponges for local treatment of methicillin-resistant Staphylococcus aureus infection. Adv Mater, 2015, 27: 3437-3443 CrossRef PubMed Google Scholar

[2] Wang F, Fang RH, Luk BT, et al. Nanoparticle-based antivirulence vaccine for the management of methicillin-resistant Staphylococcus aureus skin infection. Adv Funct Mater, 2016, 26: 1628-1635 CrossRef PubMed Google Scholar

[3] Pang Z, Hu CMJ, Fang RH, et al. Detoxification of organophosphate poisoning using nanoparticle bioscavengers. ACS Nano, 2015, 9: 6450-6458 CrossRef Google Scholar

[4] Hu CMJ, Fang RH, Wang KC, et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature, 2015, 526: 118-121 CrossRef PubMed ADS Google Scholar

[5] Gao W, Zhang L. Engineering red-blood-cell-membrane-coated nanoparticles for broad biomedical applications. AIChE J, 2015, 61: 738-746 CrossRef Google Scholar

[6] Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov, 2014, 13: 655-672 CrossRef PubMed Google Scholar

[7] Torchilin VP. Drug targeting. Eur J Pharm Sci, 2000, 11: S81-S91 CrossRef Google Scholar

[8] Kola I, Landis J. Opinion: can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov, 2004, 3: 711-716 CrossRef PubMed Google Scholar

[9] Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotech, 2007, 2: 751-760 CrossRef PubMed ADS Google Scholar

[10] Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov, 2010, 9: 615-627 CrossRef PubMed Google Scholar

[11] Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov, 2005, 4: 145-160 CrossRef PubMed Google Scholar

[12] Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res, 1986, 46: 6387–6392. Google Scholar

[13] Luk BT, Zhang L. Current advances in polymer-based nanotheranostics for cancer treatment and diagnosis. ACS Appl Mater Interfaces, 2014, 6: 21859-21873 CrossRef PubMed Google Scholar

[14] Cryan SA, Devocelle M, Moran PJ, et al. Increased intracellular targeting to airway cells using octaarginine-coated liposomes: in vitro assessment of their suitability for inhalation. Mol Pharm, 2006, 3: 104-112 CrossRef PubMed Google Scholar

[15] Qin Y, Fan W, Chen H, et al. In vitro and in vivo investigation of glucose-mediated brain-targeting liposomes. J Drug Targeting, 2010, 18: 536-549 CrossRef PubMed Google Scholar

[16] Dixit V, Van den Bossche J, Sherman DM, et al. Synthesis and grafting of thioctic acid-PEG-folate conjugates onto Au nanoparticles for selective targeting of folate receptor-positive tumor cells. Bioconjugate Chem, 2006, 17: 603-609 CrossRef PubMed Google Scholar

[17] Manjappa AS, Chaudhari KR, Venkataraju MP, et al. Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor. J Control Release, 2011, 150: 2-22 CrossRef PubMed Google Scholar

[18] Wei X, Zhan C, Shen Q, et al. A D-peptide ligand of nicotine acetylcholine receptors for brain-targeted drug delivery. Angew Chem, 2015, 127: 3066-3070 CrossRef Google Scholar

[19] Yan Z, Wang F, Wen Z, et al. LyP-1-conjugated PEGylated liposomes: a carrier system for targeted therapy of lymphatic metastatic tumor. J Controlled Release, 2012, 157: 118-125 CrossRef PubMed Google Scholar

[20] Sun X, Pang Z, Ye H, et al. Co-delivery of pEGFP-hTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated liposome. Biomaterials, 2012, 33: 916-924 CrossRef PubMed Google Scholar

[21] Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov, 2003, 2: 214-221 CrossRef PubMed Google Scholar

[22] Knop K, Hoogenboom R, Fischer D, et al. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chim Int Ed, 2010, 49: 6288-6308 CrossRef PubMed Google Scholar

[23] Rao L, Xu JH, Cai B, et al. Synthetic nanoparticles camouflaged with biomimetic erythrocyte membranes for reduced reticuloendothelial system uptake. Nanotechnology, 2016, 27: 085106 CrossRef PubMed ADS Google Scholar

[24] Théry C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol, 2009, 9: 581-593 CrossRef PubMed Google Scholar

[25] Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov, 2008, 7: 771-782 CrossRef PubMed Google Scholar

[26] Merkel TJ, Jones SW, Herlihy KP, et al. Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles. Proc Natl Acad Sci USA, 2011, 108: 586-591 CrossRef PubMed ADS Google Scholar

[27] Doshi N, Zahr AS, Bhaskar S, et al. Red blood cell-mimicking synthetic biomaterial particles. Proc Natl Acad Sci USA, 2009, 106: 21495-21499 CrossRef PubMed ADS Google Scholar

[28] Hu CMJ, Zhang L, Aryal S, et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci USA, 2011, 108: 10980-10985 CrossRef PubMed ADS Google Scholar

[29] Luk BT, Jack Hu CM, Fang RH, et al. Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles. Nanoscale, 2014, 6: 2730-2737 CrossRef PubMed ADS Google Scholar

[30] Fan Z, Zhou H, Li PY, et al. Structural elucidation of cell membrane-derived nanoparticles using molecular probes. J Mater Chem B, 2014, 2: 8231-8238 CrossRef Google Scholar

[31] Hu CMJ, Fang RH, Luk BT, et al. “Marker-of-self” functionalization of nanoscale particles through a top-down cellular membrane coating approach. Nanoscale, 2013, 5: 2664-2668 CrossRef PubMed ADS Google Scholar

[32] Piao JG, Wang L, Gao F, et al. Erythrocyte membrane is an alternative coating to polyethylene glycol for prolonging the circulation lifetime of gold nanocages for photothermal therapy. ACS Nano, 2014, 8: 10414-10425 CrossRef PubMed Google Scholar

[33] Aryal S, Hu CMJ, Fang RH, et al. Erythrocyte membrane-cloaked polymeric nanoparticles for controlled drug loading and release. Nanomedicine, 2013, 8: 1271-1280 CrossRef PubMed Google Scholar

[34] Luk BT, Fang RH, Hu CMJ, et al. Safe and immunocompatible nanocarriers cloaked in RBC membranes for drug delivery to treat solid tumors. Theranostics, 2016, 6: 1004-1011 CrossRef PubMed Google Scholar

[35] Su J, Sun H, Meng Q, et al. Long circulation red-blood-cell-mimetic nanoparticles with peptide-enhanced tumor penetration for simultaneously inhibiting growth and lung metastasis of breast cancer. Adv Funct Mater, 2016, 26: 1243-1252 CrossRef Google Scholar

[36] Xiong XB, Huang Y, Lu WL, et al. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo. J Pharm Sci, 2005, 94: 1782-1793 CrossRef PubMed Google Scholar

[37] Farokhzad OC. Using ligands to target cancer cells. Clin Adv Hematol Oncol, 2012, 10: 543–544. Google Scholar

[38] Ying M, Shen Q, Liu Y, et al. Stabilized heptapeptide A7R for enhanced multifunctional liposome-based tumor-targeted drug delivery. ACS Appl Mater Interfaces, 2016, 8: 13232-13241 CrossRef Google Scholar

[39] Gu F, Zhang L, Teply BA, et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci USA, 2008, 105: 2586-2591 CrossRef PubMed ADS Google Scholar

[40] Wei X, Gao J, Zhan C, et al. Liposome-based glioma targeted drug delivery enabled by stable peptide ligands. J Controlled Release, 2015, 218: 13-21 CrossRef PubMed Google Scholar

[41] Fang RH, Hu CMJ, Chen KNH, et al. Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles. Nanoscale, 2013, 5: 8884-8888 CrossRef PubMed ADS Google Scholar

[42] Fu Q, Lv P, Chen Z, et al. Programmed co-delivery of paclitaxel and doxorubicin boosted by camouflaging with erythrocyte membrane. Nanoscale, 2015, 7: 4020-4030 CrossRef PubMed ADS Google Scholar

[43] Khaldoyanidi SK, Glinsky VV, Sikora L, et al. MDA-MB-435 human breast carcinoma cell homo- and heterotypic adhesion under flow conditions is mediated in part by Thomsen-Friedenreich antigen-galectin-3 interactions. J Biol Chem, 2003, 278: 4127-4134 CrossRef PubMed Google Scholar

[44] Glinsky VV, Glinsky GV, Glinskii OV,et al. Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Res, 2003, 63: 3805–3811. Google Scholar

[45] Fang RH, Hu CMJ, Luk BT, et al. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett, 2014, 14: 2181-2188 CrossRef PubMed ADS Google Scholar

[46] Kawahara . lpage{415}, Infiltration of thymidine phosphorylase-positive macrophages is closely associated with tumor angiogenesis and survival in intestinal type gastric cancer. Oncol Rep, 2010, 24: 405 CrossRef Google Scholar

[47] Xuan M, Shao J, Dai L, et al. Macrophage cell membrane camouflaged mesoporous silica nanocapsules for in vivo cancer therapy. Adv Healthcare Mater, 2015, 4: 1645-1652 CrossRef PubMed Google Scholar

[48] Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell, 1991, 67: 1033-1036 CrossRef Google Scholar

[49] Parodi A, Quattrocchi N, van de Ven AL, et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotech, 2012, 8: 61-68 CrossRef PubMed ADS Google Scholar

[50] Borsig L, Wong R, Feramisco J, et al. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA, 2001, 98: 3352-3357 CrossRef PubMed ADS Google Scholar

[51] Labelle M, Begum S, Hynes RO. Platelets guide the formation of early metastatic niches. Proc Natl Acad Sci USA, 2014, 111: E3053-E3061 CrossRef PubMed ADS Google Scholar

[52] Nash G, Turner L, Scully M, et al. Platelets and cancer. Lancet Oncol, 2002, 3: 425-430 CrossRef Google Scholar

[53] Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science, 2011, 331: 1559-1564 CrossRef PubMed ADS Google Scholar

[54] Gay LJ, Felding-Habermann B. Platelets alter tumor cell attributes to propel metastasis: programming in transit. Cancer Cell, 2011, 20: 553-554 CrossRef PubMed Google Scholar

[55] Hu Q, Sun W, Qian C, et al. Anticancer platelet-mimicking nanovehicles. Adv Mater, 2015, 27: 7043-7050 CrossRef PubMed Google Scholar

[56] Li Y, Lin J, Huang Y, et al. Self-targeted, shape-assisted, and controlled-release self-delivery nanodrug for synergistic targeting/anticancer effect of cytoplasm and nucleus of cancer cells. ACS Appl Mater Interfaces, 2015, 7: 25553-25559 CrossRef Google Scholar

[57] Li Y, Lin J, Wu H, et al. Orthogonally functionalized nanoscale micelles for active targeted codelivery of methotrexate and mitomycin C with synergistic anticancer effect. Mol Pharm, 2015, 12: 769-782 CrossRef PubMed Google Scholar

[58] Ying M, Zhan C, Wang S, et al. Liposome-based systemic glioma-targeted drug delivery enabled by all-D peptides. ACS Appl Mater Interfaces, 2016, 8: 29977-29985 CrossRef Google Scholar

[59] Hu CMJ, Fang RH, Copp J, et al. A biomimetic nanosponge that absorbs pore-forming toxins. Nat Nanotech, 2013, 8: 336-340 CrossRef ADS Google Scholar

[60] Copp JA, Fang RH, Luk BT, et al. Clearance of pathological antibodies using biomimetic nanoparticles. Proc Natl Acad Sci USA, 2014, 111: 13481-13486 CrossRef ADS Google Scholar

[61] Gao W, Fang RH, Thamphiwatana S, et al. Modulating antibacterial immunity via bacterial membrane-coated nanoparticles. Nano Lett, 2015, 15: 1403-1409 CrossRef PubMed ADS Google Scholar

[62] Xuan M, Shao J, Dai L, et al. Macrophage cell membrane camouflaged au nanoshells for in vivo prolonged circulation life and enhanced cancer photothermal therapy. ACS Appl Mater Interfaces, 2016, 8: 9610-9618 CrossRef Google Scholar

[63] Zhang J, Gao W, Fang RH, et al. Synthesis of nanogels via cell membrane-templated polymerization. Small, 2015, 11: 4309-4313 CrossRef PubMed Google Scholar

[64] Daneman R. The blood-brain barrier in health and disease. Ann Neurol, 2012, 72: 648-672 CrossRef PubMed Google Scholar

[65] Wong AD, Ye M, Levy AF, et al. The blood-brain barrier: an engineering perspective. Front Neuroeng, 2013, 6: 7 CrossRef Google Scholar

[66] Ningaraj NS. Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels. J Pharm Exp Ther, 2002, 301: 838-851 CrossRef Google Scholar

Copyright 2020 Science China Press Co., Ltd. 《中国科学》杂志社有限责任公司 版权所有